EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

Perla Chami iD, Youssef Diab iD, Danny N Khalil, Hassan Azhari, William R Jarnagin, Ghassan K Abou-Alfa, James J Harding iD, Joseph Hajj, Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher Crane und 1 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242316773 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Perla Chami und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, for several types of cancers, including HCC, liver metastases have shown evidence of resistance or poor response to immunotherapies. Radiation therapy (RT) has displayed evidence of immunosuppressive effects through the upregulation of immune checkpoint molecules post-treatment. However, it was revealed that the limitations of ICIs can be overcome through the use of RT, as it can reshape the liver immune microenvironment. Moreover, ICIs are able to overcome the RT-induced inhibitory signals, effectively restoring anti-tumor activity. Owing to the synergetic effect believed to arise from the combination of ICIs with RT, several clinical trials are currently ongoing to assess the efficacy and safety of this treatment for patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmune Checkpoint InhibitorsCombined Modality TherapyImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

combination therapyhepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyradiation therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon.
  • Faculty of Medicine, University of Balamand, Beirut 1100, Lebanon.
  • Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA.
  • Department of Surgery, Weill Medical College, Cornell University, New York, NY 10021, USA.
  • Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA.
  • New York Proton Center, New York, NY 10035, USA.

ORCID-Profile: Perla Chami, Youssef Diab, James J Harding

Förderung

  • NCI NIH HHS

Zitieren

APA

Chami, P., Diab, Y., Khalil, D. N., Azhari, H., Jarnagin, W. R., Abou-Alfa, G. K., Harding, J. J., Hajj, J., Ma, J., El Homsi, M., Reyngold, M., Crane, C., & Hajj, C. (2023). Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316773

Vancouver

Chami P, Diab Y, Khalil DN, Azhari H, Jarnagin WR, Abou-Alfa GK, et al. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316773

BibTeX
@article{Chami2023,
  author = {Chami, Perla and Diab, Youssef and Khalil, Danny N and Azhari, Hassan and Jarnagin, William R and Abou-Alfa, Ghassan K and Harding, James J and Hajj, Joseph and Ma, Jennifer and El Homsi, Maria and Reyngold, Marsha and Crane, Christopher and Hajj, Carla},
  title = {Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242316773}
}
Kostenlos starten →